New therapies. Rising costs. More complexity at every level of care.

Cancer treatment is evolving rapidly, but the infrastructure to support it often lags. That is why the Clinical Pathways Congress + Cancer Care Business Exchange (CPC+CBEx) convenes the innovators shaping the future of oncology.

Held September 5–6 in Boston, CPC+CBEx is purpose-built to foster collaboration among oncology professionals, payers, and life sciences leaders—uniting diverse perspectives to advance smarter, more equitable cancer care.

In this Q&A, Steering Committee member and conference speaker Aimee Ginsburg Chesnick, PharmD, BCPS, shares why this year’s meeting matters more than ever, what makes it unique, and what attendees can expect.

What are the most pressing challenges in oncology clinical pathways, and how does CPC+CBEx address them?

Balancing innovation with accessibility remains one of the most pressing challenges—and greatest opportunities—in oncology clinical pathways today. As the pace of therapeutic advancement accelerates, the need to thoughtfully integrate novel treatments into real-world care settings is increasingly critical.

CPC+CBEx is uniquely positioned to address this dynamic. This year’s meeting features two sessions on Novel Therapy Imperatives, offering strategic insights into how emerging treatments can be incorporated into community oncology practices.

Why is cross-sector collaboration essential at an event like CPC+CBEx?

The challenges we face in cancer care are deeply interconnected. No single group can solve them in isolation.

CPC+CBEx creates a rare space for collaboration where we can break down silos, share data and insights, and co-create strategies that are both clinically sound and operationally feasible. Such alignment is essential if we want to make meaningful progress on outcomes, equity, and cost in oncology.

How is U.S. Oncology Network advancing oncology pathways, and what are you most excited about for 2025?

We have been advancing oncology pathways by focusing on what matters most: delivering evidence-based care. Through tools like Clear Value Plus, we’re helping practices make more informed, real-time decisions that incorporate precision medicine, align with value-based care models, and improve patient outcomes.

I’m looking forward to hearing how others are tackling similar challenges, like integrating novel therapies, using real-world data to refine care, and ensuring pathways remain practical at the point of care.

What sessions or themes are you most excited about in 2025?

As a pharmacist, I’m especially excited about the session moderated by Nina Chavez: “The Evolution of Pharmacist Leadership Across the Oncology Care Spectrum”, which will be held from 11:15 AM – 12:15 PM on September 5. It will highlight how far our profession has come and where we’re headed.

We’ve gathered a panel of experienced pharmacists who will share their leadership journeys, how their roles have expanded to align clinical, financial, and operational goals, and what they’ve observed over the past decade. They’ll also offer insights into what the next 10 years might look like.

Join us in Boston

CPC+CBEx is the official congress of the Journal of Clinical Pathways. Taking place September 5–6 in Boston, this two-day event features expert-led panels, scenario-based learning, and dynamic networking focused on clinical pathways, care delivery innovation, and access strategies that drive measurable impact.

Learn more and register: hmpglobalevents.com/cpc
 

Aimee Ginsburg Chesnick, PharmD, BCPS, is Director of Clinical Content Strategy for The US Oncology Network and serves on the Editorial Board of the Journal of Clinical Pathways.